Impact of the underlying etiology of growth hormone deficiency on serum IGF-I SDS levels during GH treatment in children.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

To investigate serum IGF-I SDS levels during GH treatment in children with GH deficiency, and to identify potential determinants of these levels.

Why It Was Studied

Regular monitoring of serum IGF-I levels during growth hormone (GH) therapy has been recommended, for assessing treatment compliance and safety.

Who Took Part

The age groups tagged for this paper are infants, young children and children, both men and women.

How the Study Was Run

These determinations had to have been carried out centrally, with the same immunoradiometric assay.

Serum IGF-I SDS levels were determined as a function of sex, age and pubertal stage, according to their published normative data.

What Was Measured

Regular monitoring of serum IGF-I levels during growth hormone (GH) therapy has been recommended, for assessing treatment compliance and safety.

PubMed files the paper under topics including Biomarkers, Cohort Studies, Dwarfism, Pituitary, Human Growth Hormone and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.